Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARCOT study
2024-518637-28-00Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Charcot neuroarthropathy (CN), diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM) comparing Denosumab with Saline placebo (2 arms). Primary endpoint: Time to cession of total contact cast with fracture healing. Started Nov 2024; status: completed.
02
Drugs
denosumab
03
Conditions
Charcot neuroarthropathy (CN)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-518637-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518637-28-00.